Table 2.
Trial | Treatments | Subtype | n | pCR |
---|---|---|---|---|
GeparDuo (35) |
|
All | 218 | OR 1.38 of pCR per 10% iTILs (95% CI: 1.08–1.78, P = 0.012) |
GeparTrio (35) |
|
All | 840 | OR 1.21 of pCR per 10% iTILs (95% CI: 1.08–1.35, P = 0.001) |
NeoALTTO (38) |
|
HER2+ | 387 |
|
GeparQuattro (36) |
|
HER2 + | 156 | OR 1.16 of pCR per 10% sTILs (95% CI: 1.01–1.32, P = 0.038) |
CHER-LOB (37) |
|
HER2+ | 105 | Each 10% increase in iTIL and sTIL associated with a higher probability of a pCR (adjusted OR: 2.64, 95% CI: 1.46–4.79, P = 0.001 and 1.32 95% CI: 1.08–1.6, P = 0.006, respectively) |
GeparSixto (19) |
|
HER2+ and TNBC | 580 |
|
GeparQuinto (39) |
|
ER+ and TNBC | 313 | OR 1.2 of pCR per 10% sTILs (95% CI: 1.0–1.3, P = 0.01) |
EORTC 10994 and BIG 00–01 (40) |
|
ER- | 111 |
|
Total patients | 2,710 |
pCR, pathological complete response; iTIL, intratumoral TIL; sTIL, stromal TIL; gTIL, gene expression surrogate TIL.